Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Clinical Data Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (16)	5/28/2006 4:15:06 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 39

"response marker" clda.com Surely this doesn't have to do with CYP3A4*1b variant--that has to do with metabolizing drugs--not something so specific has predicting a response to Vilazodone. Patent Portfolio Expanded- Genaissance received a notice of allowance from the U.S. Patent and Trademark Office. The allowed patent, which is co-owned with Duke University, claims testing for a common genetic variant in the CYP3A4 gene to predict whether or not an individual is a poor metabolizer of certain drugs. It is estimated at least 50 percent of all drugs, including chemotherapeutic agents and a wide variety of over-the-counter medications, are metabolized by CYP3A4. Individuals with a reduced ability to metabolize these drugs may be at risk for adverse drug reactions.